Janus Henderson Group plc (LON:0RPW)
Market Cap | 5.23B |
Revenue (ttm) | 1.98B |
Net Income (ttm) | 318.71M |
Shares Out | n/a |
EPS (ttm) | 2.04 |
PE Ratio | 16.40 |
Forward PE | n/a |
Dividend | 1.23 (2.86%) |
Ex-Dividend Date | Feb 11, 2025 |
Volume | 350 |
Average Volume | 910 |
Open | 43.10 |
Previous Close | 43.07 |
Day's Range | 43.10 - 43.10 |
52-Week Range | 22.46 - 43.25 |
Beta | 1.45 |
RSI | 44.49 |
Earnings Date | Jan 31, 2025 |
About Janus Henderson Group
Janus Henderson Group plc is an asset management holding entity. Through its subsidiaries, the firm provides services to institutional, retail clients, and high net worth clients. It manages separate client-focused equity and fixed income portfolios. The firm also manages equity, fixed income, and balanced mutual funds for its clients. It invests in public equity and fixed income markets, as well as invests in real estate and private equity. Janus Henderson Group plc was founded in 1934 and is based in London, United Kingdom with additional off... [Read more]
Financial Performance
In 2024, Janus Henderson Group's revenue was $2.47 billion, an increase of 17.67% compared to the previous year's $2.10 billion. Earnings were $399.00 million, an increase of 4.78%.
Financial numbers in USD Financial StatementsNews
Janus Henderson High-Yield Fund Q4 2024 Commentary
Janus Henderson Growth And Income Managed Account Q4 2024 Commentary
Janus Henderson Opportunistic Alpha Managed Account Q4 2024 Commentary
JANUS HENDERSON GROUP PLC Acquires Shares in Tenax Therapeutics Inc
JANUS HENDERSON GROUP PLC Acquires Shares in Tenax Therapeutics Inc
Janus Henderson Group PLC Reduces Stake in Benitec Biopharma Inc
Janus Henderson Group PLC Reduces Stake in Benitec Biopharma Inc
Janus Henderson Group PLC Expands Stake in Revvity Inc
Janus Henderson Group PLC Expands Stake in Revvity Inc
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Rentokil Initial PLC
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Rentokil Initial PLC
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Ligand Pharmaceuticals Inc
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Ligand Pharmaceuticals Inc
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Walker & Dunlop Inc
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Walker & Dunlop Inc
JANUS HENDERSON GROUP PLC Expands Stake in Blackbaud Inc
JANUS HENDERSON GROUP PLC Expands Stake in Blackbaud Inc
Janus Henderson Group PLC Adjusts Position in Immunome Inc
Janus Henderson Group PLC Adjusts Position in Immunome Inc
JANUS HENDERSON GROUP PLC Reduces Stake in Globus Medical Inc
JANUS HENDERSON GROUP PLC Reduces Stake in Globus Medical Inc
Janus Henderson Group PLC Adjusts Position in Amdocs Ltd
Janus Henderson Group PLC Adjusts Position in Amdocs Ltd
Janus Henderson Group PLC Significantly Increases Stake in Zai Lab Ltd
Janus Henderson Group PLC Significantly Increases Stake in Zai Lab Ltd
Janus Henderson Group PLC Increases Stake in Aramark with Strategic Acquisition
Janus Henderson Group PLC Increases Stake in Aramark with Strategic Acquisition
Janus Henderson Group PLC Expands Holdings in Cargo Therapeutics Inc
Janus Henderson Group PLC Expands Holdings in Cargo Therapeutics Inc
Janus Henderson Group PLC Reduces Stake in Asure Software Inc
Janus Henderson Group PLC Reduces Stake in Asure Software Inc
JANUS HENDERSON GROUP PLC Reduces Stake in Teleflex Inc
JANUS HENDERSON GROUP PLC Reduces Stake in Teleflex Inc
JANUS HENDERSON GROUP PLC Increases Stake in Soleno Therapeutics Inc
JANUS HENDERSON GROUP PLC Increases Stake in Soleno Therapeutics Inc
Janus Henderson Group PLC Expands Stake in Cimpress PLC
Janus Henderson Group PLC Expands Stake in Cimpress PLC
Janus Henderson Group PLC Increases Stake in Lexeo Therapeutics Inc
Janus Henderson Group PLC Increases Stake in Lexeo Therapeutics Inc
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Avadel Pharmaceuticals PLC
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Avadel Pharmaceuticals PLC
JANUS HENDERSON GROUP PLC Expands Stake in Ascendis Pharma AS
JANUS HENDERSON GROUP PLC Expands Stake in Ascendis Pharma AS
Janus Henderson Mid Cap Value Managed Account Q4 2024 Commentary

Janus Henderson Mid Cap Growth Managed Account Q4 2024 Commentary
The Janus Henderson Mid Cap Growth Managed Account Portfolio returned -0.05% (gross) for Q4 2024. Click here to read the full commentary.